Iroko utilizes iCeutica Inc.’s proprietary SoluMatrix™ technology to produce drug particles as a superfine powder and protects those nanoparticles from subsequent agglomeration. By reducing drug-particle size, the Solumatrix™ technology can improve drug-dissolution properties without changing chemical structures. 

With improved dissolution, formulations using this technology may offer several benefits: reduced dosing and the option to take a drug with or without food, which may enhance compliance.

SoluMatrix™ powders can be formulated as tablets or capsules and as inhalable, intranasal and injectable products.  More information about SoluMatrix can be found at www.iceutica.com/solumatrixtm.